School of Medicine Home
Departments
Department of Medicine
Research
Centers and Institutes
Ponce Clinical Research Site HIV/AIDS Clinical Trials Unit

Ponce Clinical Research Site HIV/AIDS Clinical Trials Unit

The Ponce de Leon Center (Ponce) Clinical Research Site (CRS) conducts HIV/AIDS Clinical Trials among HIV-infected and at-risk adolescents and adults.

About Us

The Ponce CRS, one of the four clinical research sites of the Emory-CDC HIV/AIDS Clinical Trials Unit, is part of the Ponce De Leon Center, an HIV care clinic within the Grady Health System that serves diverse and underrepresented minority populations.

The unit is also a part of the Emory Center for AIDS Research (CFAR) Clinical Research Core, a research group within Emory University that conducts NIH-funded HIV/AIDS research.

Clinical Trials

Who Are We?

Community Outreach

What you want to know

Key Research Areas

ACTG Studies

The Ponce Clinical Research Site (CRS) began conducting HIV/AIDS studies as part of the NIH-funded AIDS Clinical Trials Group (ACTG) in 1996. Since then, more than 500 patients with HIV have participated in these trials.

HPTN Studies

The Ponce CRS began conducting studies as part of the NIH-funded HIV Prevention Trials Network (HPTN) in 2009. Since then, more than 400 individuals at risk for HIV have participated in these trials.

COVID-19 (Moderna) Study

The mRNA-1273 vaccine was developed to prevent COVID-19. The purpose of this study was to test Moderna’s COVID-19 vaccine candidate to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives.

Portraits of the ACTG during the pandemic

CTG Investigator Carlos Del Rio and his team at the Ponce CRS prove you can still have fun with your mask on.

Research News

In July 2020, REPRIEVE held its first-ever Virtual Meeting with nearly 300 virtual attendees! Attendees heard a keynote presentation from Dr. Sandra Wanger Cordoso on HIV and CVD risk in Brazil, and 3 additional presentations from REPRIEVE Co-Investigators Dr. Kristine Erlandson, Dr. Turner Overton, and Dr. Carl Fichtenbaum. Presenters discussed their findings from their respective manuscripts in the JID supplement.

Other News of Interest

COVID-19 News Updates

More COVID-19 News Updates

New research collaboration between Emory and Pfizer aims to advance the discovery of antiviral agents for COVID-19 Mar. 13, 2023

Under the terms of a new research agreement, Emory University and Pfizer will work together to identify and evaluate potential antiviral compounds to combat COVID-19.

Extracts from two wild plants inhibit COVID-19 virus, study finds Feb. 10, 2023

In the first major screening of botanical extracts to search for potency against the virus that causes COVID-19, Emory researchers found two common wild plants that inhibit the virus’ ability to infect living cells.

Navigating COVID-19 and other respiratory diseases this semester Jan. 19, 2023

As Emory community members start the spring semester, COVID-19, influenza, respiratory syncytial virus (RSV) and other viruses remain prevalent. Here’s what you need to know to start the new year.